Search results
AstraZeneca to establish $1.5bn ADC production site in Singapore
Pharmaceutical Technology via Yahoo Finance· 4 days agoAstraZeneca is set to invest $1.5bn in a new manufacturing facility in Singapore dedicated to...
AstraZeneca Targets Ambitious $80B In Total Revenue By 2030 Through Pipeline Expansion Why Is ...
Benzinga· 4 days agoTuesday, AstraZeneca Plc AZN announced its ambitious plan to increase its total revenue to $80...
European stocks fall in Fed rate concerns; AstraZeneca lifts revenue target
Investing.com· 4 days agoEuropean stocks fall in Fed rate concerns; AstraZeneca lifts revenue target
AstraZeneca taps more China-derived tech with $19M cancer deal for Nona antibodies
Endpoints News· 2 days agoAstraZeneca on Thursday inked a license and option deal with the US offshoot of a Chinese-Dutch...
From In-House at AstraZeneca to an E-Discovery Startup: New Fileread GC Discusses Major Career Move...
Law.com· 5 days agoThe latest: E-discovery startup Fileread, which announced in early May that it hired the head of...
Why Astrazeneca (AZN) is a Great Dividend Stock Right Now
Zacks via Yahoo Finance· 3 days agoDividends are one of the best benefits to being a shareholder, but finding a great dividend stock is...
'New era of growth': AstraZeneca sets out bold plans for $80bn revenues by 2030
Evening Standard via Yahoo Finance· 4 days agoThe biggest company on London’s stock market, AstraZeneca, set out bold plans today for what it’s...
AstraZeneca earmarks $1.5B for end-to-end ADC factory in Singapore
Endpoints News· 5 days agoAstraZeneca said on Monday morning it is building a new antibody-drug conjugate facility in...
AstraZeneca (LON:AZN) Rating Reiterated by JPMorgan Chase & Co.
ETF DAILY NEWS· 2 days agoAstraZeneca (LON:AZN – Get Free Report)‘s stock had its “overweight” rating reaffirmed by equities research analysts at JPMorgan Chase & Co. in a research report issued to ...
AstraZeneca (AZN) to Build $1.5B Cancer Drug Plant in Singapore
Zacks· 5 days agoThis new plant will be AstraZeneca's (AZN) first manufacturing facility for producing novel antibody drug conjugates from start to finish. It is scheduled to open in 2029.